^
    Back
    Association details:
    Biomarker:CEACAM5 overexpression
    Cancer:Lung Non-Squamous Non-Small Cell Cancer
    Drug:Cyramza (ramucirumab) (VEGFR-2 inhibitor) +
    tusamitamab ravtansine (SAR408701) (Microtubule inhibitor, CEACAM5-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2023
    Title:

    1411P - Tusamitamab ravtansine plus ramucirumab as 2L therapy or beyond in patients with metastatic NSq NSCLC and high CEACAM5 expression (CARMEN-LC04)

    Published date:
    10/16/2023
    Excerpt:
    CARMEN-LC04 is an open-label phase 2 study (NCT04394624) assessing combination tusa rav 100 mg/m2 every 2 weeks (Q2W) + ram 8 mg/kg Q2W in patients with mNSQ NSCLC and high CEACAM5 expression (≥2+ intensity in ≥50% of tumor cells by immunohistochemistry)....Tusa rav + ram showed encouraging efficacy.
    Trial ID:
    CARMEN-LC04